Israel - heprea - Ministry of Health

rafa laboratories ltd - prednisone 2 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness

Israel - heprea - Ministry of Health

rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness

Israel - heprea - Ministry of Health

rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness

Israel - heprea - Ministry of Health

j-c health care ltd - risperidone 1 mg - film coated tablets - risperidone - risperdal is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperdal was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperdal is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperdal is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperdal is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distractibility or

Israel - heprea - Ministry of Health

sanofi israel ltd - cabazitaxel - תרכיז וממס להכנת תמיסה לאינפוזיה - cabazitaxel 60 mg / 1.5 ml - cabazitaxel - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

Israel - heprea - Ministry of Health

j-c health care ltd - abiraterone acetate - טבליה - abiraterone acetate 250 mg - abiraterone - abiraterone - zytiga is cyp 17 inbitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer

Israel - heprea - Ministry of Health

abic veterinary products ltd - florfenicol - תמיסה (פומי) - florfenicol 11.22 %w/v

Israel - heprea - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - heprea - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

Israel - heprea - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.